Refractory Status Epilepticus clinical trials

Explore recruiting refractory status epilepticus clinical trials.

Recruiting refractory status epilepticus studies right now

Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record

Also recruiting in Europe

Refractory Status Epilepticus trials registered in the EU Clinical Trials Information System (CTIS). These are outside the "near me" matcher above - open a study for full details.

A double-blind, randomized, placebo-controlled study to evaluate the efficacy, safety, and tolerability of intravenous ganaxolone added to standard of care in refractory status epilepticus

Austria, Denmark, France, Lithuania, Germany, Finland +8 more

Therapeutic confirmatory (Phase III) EU CTIS Study details

Refractory Status Epilepticus trials by city

Refractory Status Epilepticus in Toronto Refractory Status Epilepticus in Vancouver Refractory Status Epilepticus in Montreal Refractory Status Epilepticus in Calgary Refractory Status Epilepticus in Edmonton Refractory Status Epilepticus in Ottawa Refractory Status Epilepticus in Winnipeg Refractory Status Epilepticus in Quebec City Refractory Status Epilepticus in Hamilton Refractory Status Epilepticus in Kitchener Refractory Status Epilepticus in London Refractory Status Epilepticus in Halifax Refractory Status Epilepticus in New York Refractory Status Epilepticus in Los Angeles Refractory Status Epilepticus in Chicago Refractory Status Epilepticus in Houston

Other conditions

Obesity Type 2 diabetes Type 1 diabetes Prediabetes Weight loss Metabolic syndrome High cholesterol High triglycerides High blood pressure PCOS Hypothyroidism Thyroid disease Gout Fatty liver disease (NAFLD/NASH) Heart failure Coronary artery disease Atrial fibrillation Stroke Stroke recovery Peripheral artery disease Pulmonary hypertension Deep vein thrombosis Chronic kidney disease Diabetic kidney disease